𝛼SK or Searchbearish
Ro Vs TrumpRx
156 Views19 Dec 2025 08:00
TL;DR: D2C telehealth platforms like Ro and Hims & Hers scaled from high-margin ED generics to even more lucrative GLP-1s, but Trump's TrumpRx platform now threatens to commoditize their obesity business. Sacra estimates that Ro hit $598M in annualized revenue in 2024, up 66% YoY from $360M in 2023. For more, check out our full report on Ro (dataset)...
What is covered in the Full Insight:
- Introduction to Ro and Hims & Hers
- Growth of GLP-1s in Telehealth
- Impact of TrumpRx on Pricing
- Strategic Opportunities in Employer Market
- Partnerships with Pharmaceutical Companies
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 10-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Ro Vs TrumpRx19 Dec 2025
x